Blocking DCIR mitigates colitis and prevents colorectal tumors by enhancing the GM-CSF-STAT5 pathway
Haiyang Sun, Ce Tang, Soo-Hyun Chung, Xiao-Qi Ye, Yulia Makusheva, Wei Han, Masato Kubo, Shigeyuki Shichino, Satoshi Ueha, Koji Matsushima, Kazuho Ikeo, Masahide Asano, Yoichiro Iwakura
Abstract
mouse colon, which exhibits reduced infiltration of neutrophils and myeloid-derived suppressor cells. Granulocyte-macrophage colony-stimulating factor (GM-CSF) administration ameliorates DSS colitis associated with reduced Il17a and enhanced tight junction gene expression, whereas anti-GM-CSF exacerbates symptoms. Furthermore, anti-NA2, a ligand for DCIR, ameliorates colitis and prevents colorectal tumors. These observations indicate that blocking DCIR signaling ameliorates colitis and suppresses colonic tumors, suggesting DCIR as a possible target for the treatment of these diseases.